Fig. 5: Cell viability of STK11-mutant lung cancer cell lines treated with vistusertib (mTORC1/2 inhibition) or everolimus (mTORC1-only inhibition).
From: A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
A–D Cell viability of NCI-H460, A-427, NCI-A549 (STK11mut KRASmut) and ChaGoK1, NCI-H1755, CAL-12T (STK11mut KRASwt) after treatment with 0 - 10 µM vistusertib or everolimus for 48 hours, expressed as mean ± SEM from at least 3 independent experiments. Pharmacologically relevant concentrations are indicated in shaded area, calculated from previous publications63,64. E Relative luminescence for cells treated with 1µM everolimus vs. 1µM vistusertib (data presented from same experiements as described in A–D). F shows calculated IC50 values for everolimus and vistusertib in STK11 mutant NSCLC cell lines.
